Head to Head Comparison: Prime Medicine (NYSE:PRME) vs. Calidi Biotherapeutics (NYSE:CLDI)

Prime Medicine (NYSE:PRME) and Calidi Biotherapeutics (NYSE:CLDI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Analyst Recommendations

This is a summary of current ratings for Prime Medicine and Calidi Biotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	0	3	4	1	2.75
Calidi Biotherapeutics	0	0	0	0	0.00

Prime Medicine currently has a consensus target price of $9.25, suggesting a potential upside of 105.56%. Given Prime Medicine’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Prime Medicine is more favorable than Calidi Biotherapeutics.

Risk & Volatility

Prime Medicine has a beta of 2.33, suggesting that its stock price is 133% more volatile than the S&P 500. Comparatively, Calidi Biotherapeutics has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500.

Earnings & Valuation

This table compares Prime Medicine and Calidi Biotherapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$3.85 million	157.37	-$198.13 million	($1.61)	-2.80
Calidi Biotherapeutics	N/A	N/A	-$29.22 million	N/A	N/A

Calidi Biotherapeutics has lower revenue, but higher earnings than Prime Medicine.

Profitability

This table compares Prime Medicine and Calidi Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prime Medicine	N/A	-107.87%	-74.97%
Calidi Biotherapeutics	N/A	N/A	-344.45%

Institutional and Insider Ownership

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 12.5% of Calidi Biotherapeutics shares are held by institutional investors. 22.9% of Prime Medicine shares are held by company insiders. Comparatively, 6.7% of Calidi Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Prime Medicine beats Calidi Biotherapeutics on 9 of the 11 factors compared between the two stocks.

About Prime Medicine

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.